This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
3 Sector ETFs Gaining Momentum in May
by Sanghamitra Saha
After a wobbly start, Wall Street steadied in May. These sector ETFs contributed the most in Wall Street recovery on Monday.
5 Top-Performing ETF Areas of April That Are Up At Least 25%
by Sanghamitra Saha
These ETF areas showered gains in the lockdown-infected April.
Biotech ETFs Gain on New Positive Data for Gilead's Remdesivir
by Sweta Jaiswal, FRM
As the coronavirus continues to spread, the latest positive data on remdesivir is some relief in such challenging times.
Healthcare ETFs to Gain on Progress in Coronavirus Vaccine
by Sweta Jaiswal, FRM
The healthcare space is heated up with players rushing to come up with a vaccine for COVID-19.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
Ride Out the Coronavirus Mayhem With These ETF Areas
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can choose to invest for a smoother sail during the coronavirus pandemic.
6 Top-Ranked ETFs Beating the Market
by Sweta Killa
With the start of the second quarter, the U.S. stock markets have regained momentum on easing coronavirus pandemic as well as unprecedented fiscal and monetary stimulus.
Biotech ETFs Gaining on Progress in Coronavirus Treatment
by Sweta Jaiswal, FRM
The race to introduce vaccine and treatment for coronavirus is opening up opportunities, making the biotech sector a prospective space for investments.
ETFs to Rise as Gilead Drug Shows Promise in Coronavirus Cure
by Sweta Jaiswal, FRM
Gilead Sciences (GILD) has ignited a ray of hope with its recently-released positive data on the role of remdesivir as a COVID-19 treatment.
Coronavirus Testing, Vaccines & Treatments: What You Should Know
by Neena Mishra
We discuss latest developments in tests, vaccines and therapies for COVID-19.
Biotech Stocks & ETFs to Gain on Progress in COVID-19 Vaccine Development
by Sweta Jaiswal, FRM
The rampant race to introduce a vaccine for the COVID-19 is creating near-term opportunities, making the biotech sector a lucrative space for investments.
5 Low-Cost Top-Ranked ETFs to Tap at Discounted Prices
by Sanghamitra Saha
Grab these ETFs that have a solid Zacks Rank and are available at extremely low prices. These funds have a low expense ratio too.
Technology & Biotech: 2 ETFs to Watch on Outsized Volume
by Sanghamitra Saha
XLK and XBI saw massive trading volumes in yesterday trading.
4 Sector ETF Winners of Bull Market Look Resilient to Virus
by Sanghamitra Saha
These sector ETFs emerged winners in the 11-year old bull market and may survive despite the coronavirus scare.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
ETFs to Play as Goldman Lowers US Q1 GDP Outlook
by Sweta Jaiswal, FRM
We discuss some ETF areas that investors can tap as aggravating coronavirus outbreak lead to a cut in U.S. GDP growth forecast.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
3 Key Investment Themes: Zacks FEB Market Strategy
by John Blank
Where institutional money flows are where stock returns rise. This month, after I followed the money, I focused on visible long-term investing themes. Here are three worth knowing about...
Can Biotech ETFs Continue to Soar in 2020?
by Neena Mishra
We discuss coronavirus, cancer drugs, gene therapies, crispr and related biotech stocks & ETFs.
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
by Zacks Equity Research
Sector ETF report for PBE
5 ETFs to Protect Your Portfolio From Coronavirus Threat
by Sweta Killa
We have highlighted five ETFs that could benefit investors' portfolio and could provide some shelter from the crisis.